Hematology · Vitamin KRegulatory Approvalregulatorynear-term

FDA Grants Approval for Amneal's Phytonadione ANDA217734

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/22/2026, 12:32:09 AM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Amneal's Phytonadione presents a significant shift in the vitamin K market landscape, increasing competition. Portfolio teams must evaluate the implications for their existing products and strategize to safeguard market share. Regulatory context from FDA (Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026) supports the near-term read. Assessment grounded in 11 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on existing products and consider strategies to maintain market share. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Hematology · Vitamin K, 2 regulatory and 2 competitive items passed relevance filtering for Amneal.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for ZAYNICH NDA Submission by Wockhardt Bio AG (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval allows Amneal to enter the market for Phytonadione, potentially increasing competition in the vitamin K space.

Regulatory Outlook

Regulatory risk is concentrated around Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026 (FDA). Regulatory pathway relevance (approval). The approval signifies a new competitor in the market, which may lead to increased scrutiny on compliance and labeling for existing products.

Key Risks

Elevated medium regulatory exposure for Amneal could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Amneal's entry could disrupt pricing and market dynamics, potentially affecting revenue and market share for existing players in the vitamin K segment.
Portfolio teams should assess the impact of this approval on existing products and consider strategies to maintain market share.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Amneal following this approval.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Rare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of BFR-training on Stem Cells and Immune Cells in Human Skeletal Muscle
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for ZAYNICH NDA Submission by Wockhardt Bio AG
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Dual-mechanism vitamin C delivery by polyethylene glycol-23 glyceryl distearate-based niosomes via SVCT2 induction and enhanced transdermal penetration.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal
Phytonadione

Commercial impact

medium

Amneal's entry could disrupt pricing and market dynamics, potentially affecting revenue and market share for existing players in the vitamin K segment.

Regulatory impact

medium

The approval signifies a new competitor in the market, which may lead to increased scrutiny on compliance and labeling for existing products.

What to watch

Monitor market entry timelines and pricing strategies from Amneal following this approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.